Research Peptide Regulation in 2026: FDA, MHRA and WADA Explained
Why a peptide can be “removed from an FDA list” without being approved, what the July 2026 advisory votes did and did not change, and how UK and anti-doping rules apply.
2026 has been an unusually busy year for peptide regulation, and headlines such as “FDA clears BPC-157” have caused confusion. The key to reading them is that three separate systems answer three different questions — and a change in one says nothing about the others.
Three Different Questions
| Question | Who decides | What it covers |
|---|---|---|
| Is it an approved medicine? | The FDA (US) or the MHRA (UK), through a marketing authorisation | Clinical trial evidence of safety, efficacy and manufacturing quality for a specific product and use |
| Can a US pharmacy compound it? | The FDA, through the Section 503A bulk-substance rules | Whether licensed pharmacies may make individual preparations from the raw ingredient |
| Is it allowed in sport? | The World Anti-Doping Agency (WADA) | Whether athletes may use it, in or out of competition |
A handful of peptides covered in these guides are approved medicines for specific uses — for example bremelanotide (PT-141) for low sexual desire in premenopausal women, tesamorelin for HIV-associated abdominal fat, and elamipretide (SS-31) for Barth syndrome in the US. Most research peptides are not approved anywhere.
United States: Approval vs Compounding
US pharmacies may compound from a bulk ingredient only if it has a pharmacopoeial monograph, is a component of an approved drug, or appears on the FDA’s 503A bulks list. While nominations are reviewed, the FDA sorts nominated substances into interim categories; Category 2 holds substances that raise significant safety concerns. In 2023 the FDA placed more than a dozen popular peptides in Category 2, effectively stopping pharmacies from compounding them.1
April 2026 — twelve peptides removed from Category 2. On 15 April the FDA republished its interim list with the intention of removing twelve peptides from Category 2, and announced advisory committee reviews.2 Removal does not, by itself, make a substance eligible for compounding — it only takes it off the “significant safety concerns” list while it is reviewed.
The July 2026 Advisory Committee Votes
On 23–24 July the FDA’s Pharmacy Compounding Advisory Committee voted on seven of the twelve peptides. FDA scientists had recommended against all seven.3
| Peptide | Use reviewed | Vote (yes–no–abstain) |
|---|---|---|
| BPC-157 | Ulcerative colitis | 8–6–1 — recommended |
| KPV | Wound healing and inflammatory conditions | 8–6–1 — recommended |
| TB-500 (thymosin β4 fragment) | Wound healing | 8–6–1 — recommended |
| MOTS-c | Obesity and osteoporosis | 7–5–2 — recommended |
| Semax | Cerebral ischaemia, migraine and trigeminal neuralgia | 8–5–1 — recommended |
| Epitalon | Insomnia | 7–5–1 — recommended |
| Emideltide (DSIP) | Opioid withdrawal, insomnia and narcolepsy | 6–7–1 — not recommended |
What the votes mean: the recommendations are non-binding. Adding a substance to the 503A bulks list requires FDA rulemaking with public comment, and as of October 2026 the FDA had not announced a decision. None of these peptides is an approved medicine, and compounding them remains off-limits until any listing is finalised.3
Still to come: the other five peptides removed from Category 2 — LL-37, dihexa acetate, injectable GHK-Cu, PEG-MGF and melanotan II — are due to go before the committee by February 2027.2
United Kingdom: MHRA
In the UK, a product supplied for human medicinal use needs a marketing authorisation under the Human Medicines Regulations 2012, and none of the research peptides in these guides has one for the uses they are often promoted for. The MHRA has been actively enforcing this: in October 2025 it dismantled what it called the first illicit weight-loss-medicine production facility of its kind in the UK, seizing more than 2,000 unlicensed retatrutide and tirzepatide pens, and it warned that any product sold in the UK claiming to contain retatrutide outside authorised clinical trials is likely to be illegal and potentially dangerous (MHRA press release).
Sport: The WADA 2026 Prohibited List
Every peptide below is prohibited at all times — in and out of competition — under the 2026 Prohibited List, which took effect on 1 January 2026.4
| WADA section | What it names | Peptides in these guides |
|---|---|---|
| S0 — Non-approved substances | Any substance with no current approval for human therapeutic use; BPC-157 is named as an example | BPC-157 and other unapproved research peptides not covered elsewhere |
| S2.1.5 — Innate repair receptor agonists | Examples include asialo EPO and carbamylated EPO | ARA-290 acts on the innate repair receptor |
| S2.2.1 — Testosterone-stimulating peptides (males) | Including kisspeptin and its agonist analogues | Kisspeptin |
| S2.2.3 — Growth hormone, analogues and fragments | Including AOD-9604 and hGH 176-191 | HGH 191aa |
| S2.2.4 — Growth hormone releasing factors | GHRH analogues (including CJC-1295 and tesamorelin) and secretagogues (including ipamorelin) | CJC-1295, ipamorelin, tesamorelin |
| S2.3 — Growth factors | Including IGF-1 analogues, mechano growth factors and “thymosin-β4 and its derivatives e.g. TB-500” | IGF-1 LR3, TB-500 |
What “Research Use Only” Means
A “research use only” label means material is supplied for laboratory research, not for human or veterinary use. It is not a regulatory approval of any kind, and it does not make a product’s identity or purity reliable — that depends on batch-specific analytical testing. See How to Read a Peptide COA for what to check.
Limitations
Regulatory positions change quickly, and this summary reflects published information as of October 2026. Some reporting on the July votes overstated their effect (“FDA clears…”); the votes were advisory, and the FDA had not acted on them at the time of writing. Check primary sources — the FDA, MHRA and WADA — before relying on any status.
Sources
- Regulatory Affairs Professionals Society. FDA considers adding a dozen peptides to its bulk drug compounding list. 16 April 2026. RAPS
- Goodwin Procter. FDA signals potentially evolving stance toward compounding of certain peptides. 11 May 2026. Goodwin
- Steinzor P. FDA panel backs 6 peptides for compounding. AJMC. 31 July 2026. AJMC
- World Anti-Doping Agency. The 2026 Prohibited List. In force from 1 January 2026. WADA

